BRIEF—Almirall to shed its medical device aesthetics business

Spain’s largest drugmaker Almirall has entered into a definitive agreement with Celling Biosciences, based in Austin (Texas), to divest ThermiGen for an undisclosed amount.

The transaction is expected to close before or on March 29, 2019.

In 2018, Thermi generated $18 million of net sales and had 94 employees, based in Dallas (Texas).

Thermi has an installed base of more than 2,000 users with a strong presence across the USA.

Peter Guenter, chief executive of Almirall, said: "Almirall continues to refocus its business towards medical dermatology. With this divestment, Almirall completes its strategic realignment and puts Thermi business in very good hands to capture the potential of the new Arvati innovative platform."